Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid - a double-blind placebo-controlled cross-over phase IIIB study.

[1]  A. Kaider,et al.  Intranasal submucosal bevacizumab for epistaxis in hereditary hemorrhagic telangiectasia: A double‐blind, randomized, placebo‐controlled trial , 2015, Head & neck.

[2]  I. Roberts,et al.  Antifibrinolytic drugs for acute traumatic injury. , 2015, The Cochrane database of systematic reviews.

[3]  C. Collins,et al.  Intranasal tranexamic acid for the treatment of hereditary hemorrhagic telangiectasia: a case report and review of treatment options. , 2012, Cutis.

[4]  P. Peitsidis,et al.  Antifibrinolytic therapy with tranexamic acid in pregnancy and postpartum , 2011, Expert opinion on pharmacotherapy.

[5]  A. Guttmacher,et al.  International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia , 2009, Journal of Medical Genetics.

[6]  P. Vase.  Estrogen treatment of hereditary hemorrhagic telangiectasia. A double-blind controlled clinical trial. , 2009, Acta medica Scandinavica.

[7]  T. Hadar,et al.  Antiestrogen therapy for hereditary hemorrhagic telangiectasia: A double‐blind placebo‐controlled clinical trial , 2009, The Laryngoscope.

[8]  C. Shovlin,et al.  Elevated factor VIII in hereditary haemorrhagic telangiectasia (HHT): Association with venous thromboembolism , 2007, Thrombosis and Haemostasis.

[9]  C. Morales-Angulo,et al.  Tratamiento de las epistaxis en la telangiectasia hemorrágica hereditaria (enfermedad de Rendu-Osler-Weber) con ácido tranexámico , 2007 .

[10]  Africa Fernández-L,et al.  Therapeutic action of tranexamic acid in hereditary haemorrhagic telangiectasia (HHT): Regulation of ALK-1/endoglin pathway in endothelial cells , 2007, Thrombosis and Haemostasis.

[11]  U. Geisthoff,et al.  Treatment of recurrent epistaxis in HHT. , 2006, Current pharmaceutical design.

[12]  C. Sabbà,et al.  Efficacy of unusually high doses of tranexamic acid for the treatment of epistaxis in hereditary hemorrhagic telangiectasia. , 2001, The New England journal of medicine.

[13]  A. Guttmacher,et al.  Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). , 2000, American journal of medical genetics.

[14]  K. Goa,et al.  Tranexamic Acid , 1999, Drugs.

[15]  H. Saba,et al.  Brief report: treatment of bleeding in hereditary hemorrhagic telangiectasia with aminocaproic acid. , 1994, The New England journal of medicine.

[16]  P. Rutgeerts,et al.  Estrogen-progesterone treatment of Osler-Weber-Rendu disease. , 1988, Journal of clinical gastroenterology.

[17]  H. Kwaan,et al.  Fibrinolytic activity in lesions of hereditary hemorrhagic telangiectasia. , 1973, Archives of dermatology.

[18]  F. Sanz‐Rodríguez,et al.  [Treatment of epistaxes in hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber disease) with tranexamic acid]. , 2007, Acta otorrinolaringologica espanola.

[19]  T. Morishima,et al.  [Fibrinolytic activity in cutaneous lesions of hereditary hemorrhagic telangiectasia]. , 1985, Nihon Hifuka Gakkai zasshi. The Japanese journal of dermatology.

[20]  I. Nilsson.  Clinical pharmacology of aminocaproic and tranexamic acids , 1980, Journal of clinical pathology. Supplement.